Drugmaker Calls for Limit to Data Shown in Accelerated Drug Labeling

Drug Industry Daily
A A
Novartis wants the FDA to back off plans that would require drugmakers to include details of clinical trials data in labeling for drugs brought to market under accelerated approval pathways.

To View This Article:

Login

Subscribe To Drug Industry Daily